Publication Information

{'id': 'https://openalex.org/W2169737508', 'doi': 'https://doi.org/10.1158/1078-0432.ccr-11-0815', 'title': 'Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response', 'display_name': 'Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response', 'publication_year': 2011, 'publication_date': '2011-06-03', 'ids': {'openalex': 'https://openalex.org/W2169737508', 'doi': 'https://doi.org/10.1158/1078-0432.ccr-11-0815', 'mag': '2169737508', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/21632851', 'pmcid': 'https://www.ncbi.nlm.nih.gov/pmc/articles/3657705'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1158/1078-0432.ccr-11-0815', 'pdf_url': 'https://aacrjournals.org/clincancerres/article-pdf/17/14/4854/1997032/4854.pdf', 'source': {'id': 'https://openalex.org/S183149254', 'display_name': 'Clinical Cancer Research', 'issn_l': '1078-0432', 'issn': ['1078-0432', '1557-3265'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': True, 'oa_status': 'bronze', 'oa_url': 'https://aacrjournals.org/clincancerres/article-pdf/17/14/4854/1997032/4854.pdf', 'any_repository_has_fulltext': True}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5012804612', 'display_name': 'Charles J. Ryan', 'orcid': 'https://orcid.org/0000-0002-2081-3557'}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}, {'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}, {'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}], 'countries': ['US'], 'is_corresponding': True, 'raw_author_name': 'Charles J. Ryan', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I1316535847', 'https://openalex.org/I4210117453', 'https://openalex.org/I4210167126']}, {'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5101847643', 'display_name': 'Shreya Shah', 'orcid': 'https://orcid.org/0000-0001-7055-7566'}, 'institutions': [{'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}, {'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}, {'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Shreya Shah', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I1316535847', 'https://openalex.org/I4210117453', 'https://openalex.org/I4210167126']}, {'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5078910130', 'display_name': 'Eleni Efstathiou', 'orcid': 'https://orcid.org/0000-0002-3868-1396'}, 'institutions': [{'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}, {'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}, {'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Eleni Efstathiou', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I1316535847', 'https://openalex.org/I4210117453', 'https://openalex.org/I4210167126']}, {'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5105784284', 'display_name': 'Matthew R. Smith', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}, {'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Matthew R. Smith', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I1316535847', 'https://openalex.org/I4210167126', 'https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5111605855', 'display_name': 'Mary-Ellen Taplin', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}, {'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}, {'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Mary-Ellen Taplin', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I4210167126', 'https://openalex.org/I1316535847', 'https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}, {'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5043769628', 'display_name': 'Glenn J. Bubley', 'orcid': 'https://orcid.org/0000-0002-3062-643X'}, 'institutions': [{'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}, {'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}, {'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Glenn J. Bubley', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I1316535847', 'https://openalex.org/I4210117453', 'https://openalex.org/I4210167126']}, {'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5008820123', 'display_name': 'Christopher J. Logothetis', 'orcid': 'https://orcid.org/0000-0002-6365-1711'}, 'institutions': [{'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}, {'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}, {'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Christopher J. Logothetis', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}, {'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I1316535847', 'https://openalex.org/I4210117453', 'https://openalex.org/I4210167126']}, {'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5060580174', 'display_name': 'Thian Kheoh', 'orcid': 'https://orcid.org/0009-0009-0719-8631'}, 'institutions': [{'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}, {'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}, {'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Thian Kheoh', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I1316535847', 'https://openalex.org/I4210117453', 'https://openalex.org/I4210167126']}, {'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5110243588', 'display_name': 'Christine Kilian', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}, {'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}, {'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Christine Kilian', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I1316535847', 'https://openalex.org/I4210117453', 'https://openalex.org/I4210167126']}, {'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5108460394', 'display_name': 'Christopher M. Haqq', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}, {'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}, {'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Christopher M. Haqq', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I1316535847', 'https://openalex.org/I4210117453', 'https://openalex.org/I4210167126']}, {'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5105420874', 'display_name': 'Arturo Molina', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}, {'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}, {'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Arturo Molina', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}, {'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I1316535847', 'https://openalex.org/I4210117453', 'https://openalex.org/I4210167126']}, {'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5007578304', 'display_name': 'Eric J. Small', 'orcid': 'https://orcid.org/0000-0003-3191-6268'}, 'institutions': [{'id': 'https://openalex.org/I4210167126', 'display_name': 'UCSF Helen Diller Family Comprehensive Cancer Center', 'ror': 'https://ror.org/05yndxy10', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I180670191', 'https://openalex.org/I4210110664', 'https://openalex.org/I4210167126']}, {'id': 'https://openalex.org/I1316535847', 'display_name': 'Beth Israel Deaconess Medical Center', 'ror': 'https://ror.org/04drvxt59', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1316535847']}, {'id': 'https://openalex.org/I4210117453', 'display_name': 'Dana-Farber Cancer Institute', 'ror': 'https://ror.org/02jzgtq86', 'country_code': 'US', 'type': 'facility', 'lineage': ['https://openalex.org/I4210117453']}, {'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}, {'id': 'https://openalex.org/I4210087915', 'display_name': 'Massachusetts General Hospital', 'ror': 'https://ror.org/002pd6e78', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210087915', 'https://openalex.org/I48633490']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Eric J. Small', 'raw_affiliation_strings': ["Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'Dana-Farber Cancer Institute', 'Division of Hematology-Oncology, Massachusetts General Hospital', 'MD Anderson Cancer Center, Houston, Texas'], 'affiliations': [{'raw_affiliation_string': "Authors' Affiliations:\u20081Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California", 'institution_ids': ['https://openalex.org/I4210167126', 'https://openalex.org/I1316535847', 'https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'MD Anderson Cancer Center, Houston, Texas', 'institution_ids': ['https://openalex.org/I1343551460']}, {'raw_affiliation_string': 'Division of Hematology-Oncology, Massachusetts General Hospital', 'institution_ids': ['https://openalex.org/I4210087915']}, {'raw_affiliation_string': 'Dana-Farber Cancer Institute', 'institution_ids': ['https://openalex.org/I4210117453']}, {'raw_affiliation_string': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts', 'institution_ids': ['https://openalex.org/I1316535847']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 5, 'corresponding_author_ids': ['https://openalex.org/A5012804612'], 'corresponding_institution_ids': ['https://openalex.org/I1343551460', 'https://openalex.org/I1316535847', 'https://openalex.org/I4210117453', 'https://openalex.org/I4210167126', 'https://openalex.org/I4210087915'], 'apc_list': None, 'apc_paid': None, 'fwci': 24.41, 'has_fulltext': True, 'fulltext_origin': 'pdf', 'cited_by_count': 220, 'citation_normalized_percentile': {'value': 0.999969, 'is_in_top_1_percent': True, 'is_in_top_10_percent': True}, 'cited_by_percentile_year': {'min': 98, 'max': 99}, 'biblio': {'volume': '17', 'issue': '14', 'first_page': '4854', 'last_page': '4861'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10543', 'display_name': 'Prostate Cancer Treatment and Research', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10543', 'display_name': 'Prostate Cancer Treatment and Research', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11395', 'display_name': 'Radiopharmaceutical Chemistry and Applications', 'score': 0.9915, 'subfield': {'id': 'https://openalex.org/subfields/2741', 'display_name': 'Radiology, Nuclear Medicine and Imaging'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11146', 'display_name': 'Hormonal and reproductive studies', 'score': 0.9455, 'subfield': {'id': 'https://openalex.org/subfields/2712', 'display_name': 'Endocrinology, Diabetes and Metabolism'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/abiraterone-acetate', 'display_name': 'Abiraterone acetate', 'score': 0.7452711}], 'concepts': [{'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.8991864}, {'id': 'https://openalex.org/C2780192828', 'wikidata': 'https://www.wikidata.org/wiki/Q181257', 'display_name': 'Prostate cancer', 'level': 3, 'score': 0.81700945}, {'id': 'https://openalex.org/C2775832370', 'wikidata': 'https://www.wikidata.org/wiki/Q27888393', 'display_name': 'Abiraterone acetate', 'level': 5, 'score': 0.7452711}, {'id': 'https://openalex.org/C2778720950', 'wikidata': 'https://www.wikidata.org/wiki/Q424972', 'display_name': 'Prednisone', 'level': 2, 'score': 0.60737485}, {'id': 'https://openalex.org/C197934379', 'wikidata': 'https://www.wikidata.org/wiki/Q2047938', 'display_name': 'Adverse effect', 'level': 2, 'score': 0.5561547}, {'id': 'https://openalex.org/C2779343474', 'wikidata': 'https://www.wikidata.org/wiki/Q3109175', 'display_name': 'Context (archaeology)', 'level': 2, 'score': 0.54478556}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.5333647}, {'id': 'https://openalex.org/C2777899217', 'wikidata': 'https://www.wikidata.org/wiki/Q4759439', 'display_name': 'Androgen deprivation therapy', 'level': 4, 'score': 0.49453804}, {'id': 'https://openalex.org/C126894567', 'wikidata': 'https://www.wikidata.org/wiki/Q105650', 'display_name': 'Urology', 'level': 1, 'score': 0.46873412}, {'id': 'https://openalex.org/C31760486', 'wikidata': 'https://www.wikidata.org/wiki/Q7180990', 'display_name': 'Phases of clinical research', 'level': 3, 'score': 0.45914292}, {'id': 'https://openalex.org/C2776694085', 'wikidata': 'https://www.wikidata.org/wiki/Q974135', 'display_name': 'Chemotherapy', 'level': 2, 'score': 0.45317182}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.4261609}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.3759624}, {'id': 'https://openalex.org/C141071460', 'wikidata': 'https://www.wikidata.org/wiki/Q40821', 'display_name': 'Surgery', 'level': 1, 'score': 0.35290623}, {'id': 'https://openalex.org/C151730666', 'wikidata': 'https://www.wikidata.org/wiki/Q7205', 'display_name': 'Paleontology', 'level': 1, 'score': 0.0}, {'id': 'https://openalex.org/C86803240', 'wikidata': 'https://www.wikidata.org/wiki/Q420', 'display_name': 'Biology', 'level': 0, 'score': 0.0}], 'mesh': [{'descriptor_ui': 'D000730', 'descriptor_name': 'Androstadienes', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D018931', 'descriptor_name': 'Antineoplastic Agents, Hormonal', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D001859', 'descriptor_name': 'Bone Neoplasms', 'qualifier_ui': 'Q000556', 'qualifier_name': 'secondary', 'is_major_topic': True}, {'descriptor_ui': 'D011471', 'descriptor_name': 'Prostatic Neoplasms', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D011471', 'descriptor_name': 'Prostatic Neoplasms', 'qualifier_ui': 'Q000473', 'qualifier_name': 'pathology', 'is_major_topic': True}, {'descriptor_ui': 'D000069501', 'descriptor_name': 'Abiraterone Acetate', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000368', 'descriptor_name': 'Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000369', 'descriptor_name': 'Aged, 80 and over', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000730', 'descriptor_name': 'Androstadienes', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000730', 'descriptor_name': 'Androstadienes', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D018931', 'descriptor_name': 'Antineoplastic Agents, Hormonal', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D018931', 'descriptor_name': 'Antineoplastic Agents, Hormonal', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D001859', 'descriptor_name': 'Bone Neoplasms', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D001859', 'descriptor_name': 'Bone Neoplasms', 'qualifier_ui': 'Q000473', 'qualifier_name': 'pathology', 'is_major_topic': False}, {'descriptor_ui': 'D001859', 'descriptor_name': 'Bone Neoplasms', 'qualifier_ui': 'Q000000981', 'qualifier_name': 'diagnostic imaging', 'is_major_topic': False}, {'descriptor_ui': 'D001842', 'descriptor_name': 'Bone and Bones', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D001842', 'descriptor_name': 'Bone and Bones', 'qualifier_ui': 'Q000473', 'qualifier_name': 'pathology', 'is_major_topic': False}, {'descriptor_ui': 'D001842', 'descriptor_name': 'Bone and Bones', 'qualifier_ui': 'Q000000981', 'qualifier_name': 'diagnostic imaging', 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008297', 'descriptor_name': 'Male', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008875', 'descriptor_name': 'Middle Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D009362', 'descriptor_name': 'Neoplasm Metastasis', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D009919', 'descriptor_name': 'Orchiectomy', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D017430', 'descriptor_name': 'Prostate-Specific Antigen', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D017430', 'descriptor_name': 'Prostate-Specific Antigen', 'qualifier_ui': 'Q000097', 'qualifier_name': 'blood', 'is_major_topic': False}, {'descriptor_ui': 'D011471', 'descriptor_name': 'Prostatic Neoplasms', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011471', 'descriptor_name': 'Prostatic Neoplasms', 'qualifier_ui': 'Q000175', 'qualifier_name': 'diagnosis', 'is_major_topic': False}, {'descriptor_ui': 'D011859', 'descriptor_name': 'Radiography', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D016896', 'descriptor_name': 'Treatment Outcome', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 4, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.1158/1078-0432.ccr-11-0815', 'pdf_url': 'https://aacrjournals.org/clincancerres/article-pdf/17/14/4854/1997032/4854.pdf', 'source': {'id': 'https://openalex.org/S183149254', 'display_name': 'Clinical Cancer Research', 'issn_l': '1078-0432', 'issn': ['1078-0432', '1557-3265'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': True, 'landing_page_url': 'https://europepmc.org/articles/pmc3657705', 'pdf_url': 'https://europepmc.org/articles/pmc3657705?pdf=render', 'source': {'id': 'https://openalex.org/S4306400806', 'display_name': 'Europe PMC (PubMed Central)', 'issn_l': None, 'issn': None, 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1303153112', 'host_organization_name': 'European Bioinformatics Institute', 'host_organization_lineage': ['https://openalex.org/I1303153112'], 'host_organization_lineage_names': ['European Bioinformatics Institute'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': 'acceptedVersion', 'is_accepted': True, 'is_published': False}, {'is_oa': True, 'landing_page_url': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657705', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764455111', 'display_name': 'PubMed Central', 'issn_l': None, 'issn': None, 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': 'acceptedVersion', 'is_accepted': True, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/21632851', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1158/1078-0432.ccr-11-0815', 'pdf_url': 'https://aacrjournals.org/clincancerres/article-pdf/17/14/4854/1997032/4854.pdf', 'source': {'id': 'https://openalex.org/S183149254', 'display_name': 'Clinical Cancer Research', 'issn_l': '1078-0432', 'issn': ['1078-0432', '1557-3265'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'score': 0.79, 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 22, 'referenced_works': ['https://openalex.org/W1983971143', 'https://openalex.org/W2003955264', 'https://openalex.org/W2014476883', 'https://openalex.org/W2048351536', 'https://openalex.org/W2064360128', 'https://openalex.org/W2069243419', 'https://openalex.org/W2072395954', 'https://openalex.org/W2094260968', 'https://openalex.org/W2101606728', 'https://openalex.org/W2110188261', 'https://openalex.org/W2113569308', 'https://openalex.org/W2116458141', 'https://openalex.org/W2117296712', 'https://openalex.org/W2133489902', 'https://openalex.org/W2137996608', 'https://openalex.org/W2139248078', 'https://openalex.org/W2141569270', 'https://openalex.org/W2155679349', 'https://openalex.org/W2161775120', 'https://openalex.org/W2170544517', 'https://openalex.org/W2171041379', 'https://openalex.org/W2401642415'], 'related_works': ['https://openalex.org/W4286516538', 'https://openalex.org/W4200552296', 'https://openalex.org/W2986294136', 'https://openalex.org/W2913908103', 'https://openalex.org/W2903095994', 'https://openalex.org/W2753537866', 'https://openalex.org/W2728894889', 'https://openalex.org/W2035098213', 'https://openalex.org/W2033949587', 'https://openalex.org/W1988476842'], 'abstract_inverted_index': {'Abstract': [0], 'Purpose:': [1], 'Abiraterone': [2], 'is': [3, 10, 257], 'an': [4, 89], 'oral': [5], 'inhibitor': [6], 'of': [7, 36, 86, 88, 98, 131, 139, 147, 192, 197, 214, 221, 264, 273], 'CYP17,': [8], 'which': [9], 'essential': [11], 'for': [12, 71, 180], 'androgen': [13], 'biosynthesis.': [14], 'This': [15], 'multicenter': [16], 'study': [17], 'assessed': [18], 'its': [19], 'efficacy': [20, 72], 'in': [21, 63, 96, 104, 121, 129, 136, 145, 157, 187, 190, 212, 250], 'patients': [22, 50, 177, 218], 'with': [23, 40, 57, 107, 234, 252], 'castration-resistant': [24], 'prostate': [25], 'cancer': [26], '(CRPC),': [27], 'without': [28], 'prior': [29, 235], 'chemotherapy': [30], 'or': [31, 101, 110, 118, 141, 202, 219], 'CYP17-targeted': [32], 'therapy,': [33, 87], 'and': [34, 44, 73, 164, 172, 195, 232, 248, 271], 'frequency': [35], 'bone': [37, 181, 207, 265], 'scans': [38], 'discordant': [39], 'prostate-specific': [41], 'antigen': [42], '(PSA)': [43], 'clinical': [45], 'response.': [46], 'Experimental': [47], 'Design:': [48], 'Thirty-three': [49], 'received': [51], 'abiraterone': [52, 237, 243], 'acetate': [53], '1,000': [54], 'mg': [55, 60], 'daily': [56, 62], 'prednisone': [58, 245], '5': [59], 'twice': [61], 'continuous': [64], '28-day': [65], 'cycles.': [66], 'Patients': [67], 'were': [68, 143, 169, 178, 228, 246], 'evaluated': [69], 'monthly': [70], 'safety.': [74], 'Bone': [75], 'scan': [76, 108, 182, 208, 266], 'flare': [77, 209, 267], 'was': [78, 127, 185, 210], 'defined': [79], 'as': [80], 'the': [81, 261], 'combination,': [82], 'after': [83], '3': [84, 112], 'months': [85, 113], 'interpreting': [90], "radiologist's": [91, 188], 'report': [92, 189], 'indicating': [93], '“disease': [94], 'progression”': [95], 'context': [97], 'a': [99], '50%': [100, 117, 140], 'more': [102, 119, 142], 'decline': [103, 120], 'PSA': [105, 122, 137, 152, 167], 'level,': [106], 'improvement': [109, 201], 'stability': [111], 'later.': [114], 'Results:': [115], 'A': [116], 'level': [123, 138], 'at': [124], 'week': [125], '12': [126, 191, 198], 'confirmed': [128], '22': [130], '33': [132, 148, 222], '(67%)': [133], 'patients.': [134, 150, 159, 225], 'Declines': [135], 'seen': [144], '26': [146], '(79%)': [149], 'Undetectable': [151], 'levels': [153], '(≤0.1': [154], 'ng/mL)': [155], 'occurred': [156], '2': [158], 'Median': [160], 'time': [161, 165], 'on': [162, 268], 'therapy': [163], 'to': [166, 242, 259], 'progression': [168], '63': [170], 'weeks': [171], '16.3': [173], 'months,': [174], 'respectively.': [175], 'Twenty-three': [176], 'evaluable': [179, 217], 'flare.': [183], 'Progression': [184], 'indicated': [186], '23': [193, 215], '(52%),': [194], '11': [196, 213, 220], 'subsequently': [199], 'showed': [200], 'stability.': [203], 'As': [204], 'prospectively': [205], 'defined,': [206], 'observed': [211], '(48%)': [216], '(33%)': [223], 'enrolled': [224], 'Adverse': [226], 'events': [227], 'typically': [229], 'grade': [230], '1/2': [231], 'consistent': [233], 'published': [236], 'reports.': [238], 'Conclusion:': [239], 'Clinical': [240], 'responses': [241], 'plus': [244], 'frequent': [247], 'durable': [249], 'men': [251], 'metastatic': [253], 'CRPC.': [254], 'Further': [255], 'investigation': [256], 'needed': [258], 'clarify': [260], 'confounding': [262], 'effect': [263], 'patient': [269], 'management': [270], 'interpretation': [272], 'results.': [274], 'Clin': [275], 'Cancer': [276], 'Res;': [277], '17(14);': [278], '4854–61.': [279], '©2011': [280], 'AACR.': [281]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2169737508', 'counts_by_year': [{'year': 2024, 'cited_by_count': 7}, {'year': 2023, 'cited_by_count': 6}, {'year': 2022, 'cited_by_count': 6}, {'year': 2021, 'cited_by_count': 7}, {'year': 2020, 'cited_by_count': 3}, {'year': 2019, 'cited_by_count': 11}, {'year': 2018, 'cited_by_count': 18}, {'year': 2017, 'cited_by_count': 15}, {'year': 2016, 'cited_by_count': 20}, {'year': 2015, 'cited_by_count': 28}, {'year': 2014, 'cited_by_count': 28}, {'year': 2013, 'cited_by_count': 32}, {'year': 2012, 'cited_by_count': 30}], 'updated_date': '2024-12-10T00:17:10.435187', 'created_date': '2016-06-24'}